Right heart thrombi in pulmonary embolism Results from the international cooperative pulmonary embolism registry by Torbicki, Adam et al.
Right Heart Thrombi in Pulmonary Embolism
Results From the International Cooperative Pulmonary Embolism Registry
Adam Torbicki, MD,* Nazzareno Galie´, MD,† Anna Covezzoli, BS,‡ Elisa Rossi, BS,‡
Marisa De Rosa, PHD,‡ Samuel Z. Goldhaber, MD,§ on behalf of the ICOPER Study Group
Warsaw, Poland; Bologna, Italy; and Boston, Massachusetts
OBJECTIVES This study was designed to investigate the prevalence and prognostic significance of right
heart thrombi (RHTh) in pulmonary embolism.
BACKGROUND Most reports about patients with RHTh are small case series. We analyzed data referring to
RHTh among 2,454 consecutive pulmonary embolism patients enrolled in the International
Cooperative Pulmonary Embolism Registry.
METHODS Of the 2,454 patients, 1,113 had results available from baseline echocardiography. We
compared the 42 patients with RHTh versus 1,071 without RHTh.
RESULTS Patients with RHTh had shorter duration of symptoms (2.2  2.9 days vs. 4.3  6.0 days,
p  0.013), lower systolic blood pressure (BP) (116.0  28.8 vs. 125.7  25.0 mm Hg, p 
0.008), and more frequent right ventricular hypokinesis (64% vs. 40%, p  0.002) and
congestive heart failure (26% vs. 13%, p  0.024); but they had similar age (62.9 vs. 62.5
years), arterial oxygen pressure (71.3  26.0 vs. 69.5  30.5 mm Hg), and prevalence of
cancer (14% vs. 19%). The overall mortality rate at 14 days and at three months was higher
in patients with RHTh (21% vs. 11%, p  0.032, and 29% vs. 16%, p  0.036). The difference
in early mortality was observed almost entirely within the subgroup of patients treated with
heparin alone (23.5% vs. 8%, p 0.02), despite similar clinical severity at presentation (systolic BP
122.2  24.2 vs. 127.8  24.1 mm Hg, hypotension in 5.9% vs. 3.4% patients).
CONCLUSIONS Among patients with acute pulmonary embolism, RHTh is usually found in those more
hemodynamically compromised but is also a marker of worse prognosis in initially apparently
stable patients treated with heparin alone. (J Am Coll Cardiol 2003;41:2245–51) © 2003
by the American College of Cardiology Foundation
Small case series have described the prevalence, natural
history, and prognostic significance of right heart thrombi
(RHTh) in pulmonary embolism (1–6). The International
Cooperative Pulmonary Embolism Registry (ICOPER) of
2,454 prospectively enrolled patients from 52 hospitals in
seven countries provided a unique opportunity to study
further this clinical problem. Almost half of the patients
underwent baseline echocardiography. We achieved three
months’ follow-up of vital status in 98% of patients. We
correlated findings on baseline echocardiography with clin-
ical management and outcome (7).
METHODS
The International Cooperative Pulmonary Embolism Reg-
istry enrolled consecutive patients with acute pulmonary
embolism (PE) between January 1995 and November 1996.
The principal inclusion criterion was acute PE diagnosed
according to clinical routine of the reporting center within
31 days of the onset of symptoms. No recommendations
were made regarding the use of echocardiography, general
diagnostic strategy, or therapeutic approach. A detailed
electronic case report form was filled out for each patient by
participating institutions, using an online system devised by
CINECA, an interuniversity consortium of 15 Italian uni-
versities. This report included information on the history
and clinical presentation at the time of PE diagnosis as well
as on the presence of echocardiographic signs of right
ventricular (RV) dysfunction and the presence of intracar-
diac thrombi. No other echocardiographic variables were
requested. We analyzed patients with () and without ()
RHTh with respect to clinical characteristics and therapy.
We compared the differences by chi-square test (for cate-
gorical variables) and Mann-Whitney U test (for continuous
variables). We assessed the absence of normal distribution
of quantitative variables using the Kolmogorov-Smirnov
test. Cumulative probabilities of surviving and their 95%
confidence intervals were evaluated by the Kaplan-Meier
method. Survival rates for the groups with and those
without RHTh were compared using the log-rank test. The
mortality rate was also evaluated according to treatment
received. We also performed a subgroup analysis excluding
patients with right heart (RH) catheters and pacemaker
electrodes. Multivariate analysis was performed using Cox
proportional-hazards regression analysis.
RESULTS
Of 2,454 patients, 1,135 were assessed by echocardiography,
of whom 42 (4%) had RHTh and 1,071 did not. Twenty-
two patients in whom RHTh was neither reported nor
unequivocally stated as absent were excluded from further
analysis (Fig. 1). The use of objective diagnostic tests for
venous thromboembolism was similar in RHTh() and
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RHTh() patients: lung scintigraphy was performed in
79% vs. 79%, pulmonary angiography in 10% vs. 21%, and
lower limbs were objectively assessed for venous thrombosis
in 40% vs. 53% of patients (all non-significant).
The RHTh() patients were more hemodynamically
compromised than the RHTh() patients, with lower
systolic blood pressure, higher heart rate (HR), and more
frequent RV hypokinesis on echocardiography (Table 1).
The RHTh() patients also had double the frequency of
clinical congestive heart failure (CHF) and more often had
right bundle branch block on electrocardiogram. Compared
with RHTh(), RHTh() patients had a shorter time
from onset of symptoms to diagnosis (2.2  2.9 days vs. 4.3
 6.0 days, p  0.013) and from onset of symptoms to
initiation of treatment of pulmonary embolism (2.2  3.0
days vs. 4.4  6.2 days, p  0.013).
With respect to similarities, age, prevalence of dyspnea,
chest pain, and blood gases were almost identical in
RHTH() patients and RHTh() patients, as was the
frequency of chronic obstructive pulmonary disease
(COPD) and cancer. However, treatment was strikingly
different between the two groups: 57% of RHTh() pa-
tients received thrombolysis, compared with 20% in the
RHTh() group and 13% in the overall ICOPER cohort.
Embolectomy was performed in four RHTh() patients
(10%) and only in 14 RHTh() patients (1%), most of
whom were treated with heparin alone (76%) (Table 1).
The overall mortality rate at 14 days and at three months
was twice as high in RHTh() patients: 21% versus 11%
(p  0.032) and 29% versus 16% (p  0.036), respectively
(Fig. 2). The difference in early mortality was more marked
Table 1. Characteristics of Patients With () and Without () RHTh
RHTh() RHTh() p*
Number of patients 42 1,071
Demographics and history
Age (yrs) 62.9  13.3 62.5  16.4 n.s.
Female gender 52% 56% n.s.
Cancer 14% 19% n.s.
Congestive heart failure 26% 13% 0.024
COPD 12% 13% n.s.
Central venous catheters 7% 8% n.s.
Pacemaker wires 5% 1% Not possible
At presentation
Dyspnea 83% 88% n.s.
Chest pain 46% 47% n.s.
Syncope 24% 16% n.s.
Heart rate (beats/min) 107.2  19.5 101.3  22.0 0.030
Systolic blood pressure (mm Hg) 116.0  28.8 125.7  25.0 0.008
Systolic blood pressure 90 mm Hg 14% 5% 0.012
PaO2 (mm Hg) 71.3  26.0 69.5  30.5 n.s.
PaCO2 (mm Hg) 32.0  8.3 33.7  8.6 n.s.
Respiratory rate (beats/min) 27.8  8.0 25.3  9.5 0.037
Normal electrocardiogram 12% 24% n.s.
Atrial fibrillation 12% 12% n.s.
Right bundle branch block 27% 13% 0.023
RV hypokinesis at echo 64% 40% 0.002
DVT diagnosed 40% 53% n.s.
Treatment used
Heparin 40% 76%  0.001
Thrombolysis 57% 20%  0.001
IVC filter 12% 12% n.s.
Embolectomy† 10% 1%  0.001
Outcome
Mortality at 14 days 21% 11% 0.032‡
Mortality at 3 months 29% 16% 0.036‡
*p-value refers to chi-square test (with Yates continuity correction) for categorical variables and to Mann-Whitney test for
quantitative variables. We used Mann-Whitney test instead of t test because of absence of normality distribution of variables.
†One of four patients with RHTh and 10 of 14 patients without RHTh underwent catheter embolectomies; the remaining
underwent surgical embolectomies. ‡p value refers to Log-rank test from Kaplan-Meier survival analysis.
COPD  chronic obstructive lung disease; DVT  deep vein thrombosis; IVC  inferior vena cava; n.s.  not significant;
RHTh  right heart thrombi; RV  right ventricle.
Abbreviations and Acronyms
CHF  congestive heart failure
COPD  chronic obstructive pulmonary disease
HR  heart rate
ICOPER  International Cooperative Pulmonary
Embolism Registry
PE  pulmonary embolism
RH  right heart
RV  right ventricle/ventricular
RHTh  right heart thrombi
2246 Torbicki et al. JACC Vol. 41, No. 12, 2003
Right Heart Thrombi in Pulmonary Embolism June 18, 2003:2245–51
(mortality at 14 days 22% vs. 10%, p  0.026) after 102
patients with RH catheters and electrodes potentially pro-
moting local thrombosis were excluded.
The most evident difference in prognosis was found
among patients treated with heparin alone (Tables 2 and 3):
mortality at 14 days was 23.5% in RHTh() versus 8% in
RHTh() (p  0.02) (Table 2) and 25% vs. 7.2% (p 
0.007) after excluding patients with central catheters and
electrodes. Despite these differences in outcome, markers of
clinical severity were not significantly different between
RHTh() and RHTh() patients treated with heparin
alone (Tables 4 and 5).
Mortality was similar in RHTh() patients treated with
heparin alone and in RHTh() patients treated with
Figure 1. The International Cooperative Pulmonary Embolism Registry (ICOPER) database as a source of information on the presence () or absence
() of right heart thrombi (RHTh). pts  patients.
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thrombolysis. However, thrombolysis-treated patients had a
non-significant trend toward more severe hemodynamic
compromise, with lower mean systolic blood pressure of 113
 31.3 vs. 122.2 24.2 mm Hg, higher mean HR of 111.5
 21.6 vs. 102.3  15.0 beats/min, more frequent hypo-
tension (16.7% vs. 5.9%), and more frequent RV hypoki-
nesis on echocardiography.
Multivariate analysis was performed on 799 patients, with
information about all risk factors identified as independent
contributors to prognosis in the main ICOPER database.
When analyzed together with age, CHF, cancer, COPD,
systemic arterial hypotension, RV hypokinesis on echocar-
diogram, and abnormally slow respiratory rate, RHTh did
not provide any further contribution to the model.
To assess whether performing echocardiography affected
the selection of patients with pulmonary embolism, Table 6
compares baseline characteristics, treatment, and outcome
of patients according to whether they underwent echocar-
diography. Thrombolytic treatment was much more fre-
quently used among patients undergoing echocardiography
(22% vs. 5%, p 0.001). However, mortality at 14 days and
three months was similar for the patients examined and for
those not examined with echocardiography.
DISCUSSION
In ICOPER, RHTh was infrequent. Our data demonstrate
that patients with RHTh are more hemodynamically com-
promised at the time of diagnosis than patients without
RHTh, as suggested by lower systemic arterial pressure,
higher prevalence of hypotension, higher HR, and frequent
RV hypokinesis on echocardiography (8). Also, patients
with RHTh more often had CHF. Thus, stasis in the
dilated RH due either to acute PE or preexisting CHF, or
both, seemed to enhance the risk of RHTh, regardless of
whether it was due to in situ thrombosis or to entrapment of
transiting thrombi.
Table 3. Mortality Rate at 3 Months, in Patients With () and
Without () RHTh According to Reported Treatment
Reported
Treatment
RHTh() RHTh()
Log-Rank
Test
p valuen/N
Mortality
Rate n/N
Mortality
Rate
Heparin 5/17 29.4% 117/813 14.3% 0.063
Thrombolysis 7/24 29.2% 45/217 20.7% n.s.
Embolectomy 1/4 25.0% 5/14 35.7% n.a.*
Abbreviations as in Table 2.
Figure 2. Three months’ survival according to the presence () or absence () of right heart thrombi (RHTh) at echocardiographic examination in a patient
with acute pulmonary embolism.
Table 2. Mortality Rate at 14 days, in Patients With () and
Without () RHTh According to Reported Treatment
Reported
Treatment
RHTh() RHTh()
Log-Rank
Test
p valuen/N
Mortality
Rate n/N
Mortality
Rate
Heparin 4/17 23.5% 65/813 8.0% 0.02
Thrombolysis 5/24 20.8% 37/217 17.1% n.s.
Embolectomy 1/4 25.0% 4/14 28.6% n.a.*
n.a.  not assessed owing to low number of cases; n.s.  not significant; RHTh 
right heart thrombi.
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The role of local stasis as a prerequisite for RHTh is
supported by the observation that the majority (88%) of
patients with RHTh in ICOPER had no other factors
promoting local thrombosis such as central catheters or
electrode wires. Moreover, cancer, a common and potent
factor inducing thrombophilia, was not more frequent
among RHTh() than RHTh() patients. In contrast to
hemodynamics, age, prevalence of COPD, and arterial
blood gases were similar in RHTh() patients and
RHTh() patients.
Assessment of prognosis is of crucial importance for the
therapeutic choices in patients with pulmonary embolism.
We found that those with RHTh had a worse 14-day as
well as three-month outcome when compared to those
without RHTh. Interestingly, mortality was higher in
RHTh() patients, despite much shorter delay from onset
of symptoms to diagnosis and treatment in this group. One
explanation may be that the RHTh, especially when in
transit from the peripheral veins, usually appears in the early
phase of acute venous thromboembolic disease and is usually
fatal if undiagnosed and thus left untreated. Another expla-
nation may be that echocardiographic documentation of a
RHTh immediately establishes the diagnosis of pulmonary
embolism, without the need to recur to other imaging tests
that might delay both diagnosis and treatment. This would
imply that earlier diagnosis and initiation of treatment does
not outweigh the increased risk of death related to RHTh.
Unfortunately, an independent causative effect of RHTh
on mortality could not be unequivocally confirmed, because
multivariate analysis involving all prognostic risk factors
identified in the main ICOPER database analysis was
limited to 799 patients and failed to confirm an independent
prognostic value of RHTh. Therefore, owing to coexisting
hemodynamic differences between RHTh() and
RHTh() patients, it is unclear whether RHTh is a direct
cause or just a marker of adverse outcome.
As was the case with Kinney and Wright (9), we found no
major differences in survival between the heparin, throm-
bolytic, and surgical treatment of RHTh. However,
ICOPER provided a unique opportunity to compare the
clinical characteristics and outcome of RHTh() and of
similarly treated RHTh() patients.
Interestingly, the high 23.5% mortality at 14 days among
RHTh() patients treated with heparin alone contrasted
markedly with the 8% mortality of RHTh() patients
treated in the same way. This could not be attributed simply
to the slight differences in severity of hemodynamic com-
promise. Mortality was also high (20.8%) among RHTh()
patients who received thrombolytic treatment, but this
could be explained by a high prevalence of hypotension
(16.7%) and RV dysfunction (76.2%) within this subgroup.
In contrast to patients who were treated with heparin alone,
those who received thrombolysis had similar mortality,
regardless of the presence or absence of RHTh.
Taken together, these observations suggest that heparin
alone might not be adequate treatment for patients with
RHTh, even among those who appear clinically stable. A
similar conclusion was reached by Rose et al. Their analysis
of outcome of 177 published case reports revealed 28.6%
mortality in patients with RHTh treated with heparin
alone, compared to 11.3% mortality among patients with
thrombolysis (10). Surprisingly few ICOPER patients with
RHTh underwent open surgical embolectomy, making
statistical analysis of this interesting subgroup impossible
(11).
Limitations of the trial. This is a prospective registry and
not a randomized trial. In order not to exclude most sick
patients, a predefined diagnostic algorithm for pulmonary
embolism was not enforced. Therefore, we cannot exclude
some influence of diagnostic errors on our results, though
the use of objective diagnostic tests was similar in
RHTh() patients and RHTh() patients. As in most
registries, neither diagnostic work-up nor therapy was
controlled. No detailed information on the morphology and
mobility of RHTh was available. Therefore, differentiation
between an in situ and an in-transit RHTh could not be
established other than by identifying coexisting risk factors
for local thrombosis, such as RH catheters and electrode
wires. We could not precisely assess the sequence of events
as far as echo and initiation of treatment are concerned.
Table 4. Comparison of Clinical Characteristics of Patients
Treated With Heparin Only, According to the Presence () or
Absence () of RHTh
RHTh()
n  17
RHTh()
n  813 p Value
Age 70 yrs 5 (29.4%) 307 (37.8%) n.s.
Cancer 3 (17.6%) 170 (21.0%) n.s.
RV hypokinesis 9 (52.9%) 246 (30.8%) n.s. (p  0.051)
Respiratory rate 20/min 9 (60.0%) 398 (65.2%) n.s.
Respiratory rate 26.3  7.8 25.1  9.9 n.s.
Hypotension
(SBP  90 mm Hg)
1 (5.9%) 27 (3.4%) n.s.
SBP (mm Hg) 122.2  24.2 127.8  24.1 n.s.
HR (50 or
100 beats/min)
9 (52.9%) 347 (42.9) n.s.
HR (beats/min) 102.3  15.0 99.9  21.5 n.s.
PO2 (mm Hg) 70.3  10.8 69.6  28.2 n.s.
PCO2 (mm Hg) 34.1  8.9 33.8  7.7 n.s.
HR  heart rate; RV  right ventricular; SBP  systolic blood pressure. Other
abbreviations as in Table 2.
Table 5. Distribution of Clinical Severity Factors According to
the Presence or Absence of RHTh in Patients Treated With
Heparin Alone
Clinical Severity
Factors*
RHTh() RHTh()
N % N %
2 factors 12 70.6% 574 70.6%
2 factors 5 29.4% 239 29.4%
Total 17 100% 813 100%
*According to the results of the analysis of ICOPER Registry Database Clinical
severity factors consist of age  70 years, cancer, right ventricular hypokinesis,
respiratory rate  20/min, systolic blood pressure  90 mm Hg, heart rate  50 or
 100 beats/min.
RHTh  right heart thrombus.
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Finally, no echocardiographic follow-up assessing the effect
of treatment on the morphology and mobility of the RHTh
was reported.
Importantly, half of the patients enrolled in the ICOPER
were not referred for echocardiography. They were slightly
less hemodynamically compromised than those in whom
this test was performed. Therefore, the prevalence of RHTh
in unselected patients with PE could be even lower than
3.8%. Previous reports suggesting much higher prevalence
of RHTh (7% to 18%) came from series collected among
patients with PE who were likely to be more hemodynam-
ically compromised, such as those admitted to an intensive
care unit (4,6) or presenting with echocardiographic signs of
RV overload (3).
Conclusions. In the context of acute pulmonary embolism,
the RHTh is infrequent and usually found in more hemo-
dynamically compromised patients with shorter duration of
symptoms. The RHTh also indicates higher risk in patients
whose clinical condition otherwise seems to permit treat-
ment with heparin alone. Whether more aggressive therapy,
such as thrombolysis or embolectomy, would improve prog-
nosis remains to be determined.
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